TTP399: an investigational liver-selective glucokinase (GK) activator as a potential treatment for type 2 diabetes
Sign Up to like & getrecommendations! Published in 2019 at "Expert Opinion on Investigational Drugs"
DOI: 10.1080/13543784.2019.1654993
Abstract: ABSTRACT Introduction: Type 2 diabetes is a complex metabolic disorder defined by hyperglycemia which occurs because of impaired insulin secretion and sensitivity. There is an ongoing need to develop novel therapies that are effective and… read more here.
Keywords: treatment type; activator potential; type diabetes; glucokinase activator ... See more keywords